MarginsXMarginsX
Home › Markets › Health Care › NBP

NovaBridge Biosciences (NBP)

NBP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.7915
-6.87% on the day
Market cap
$91.3M
Micro cap
Revenue · 2023
$632K
Prior year not contiguous
Net income · 2023
-$207.7M
-32868.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/0001778016-26-000002-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerNBP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryChina
IPO year2020
SEC CIK0001778016

Financials · 2023

LineValue
Revenue$632K
Net income-$207.7M
Operating income-$72.0M
Net margin-32868.5%
Operating margin-11395.1%
Revenue growthNo prior-year revenue to compare
Cash$291.5M
Total assets$368.9M
P/E (computed)Net income was not positive
P/S (computed)144.5×

Warning signs

Cash runway
122.7 months
$210.6M cash at December 31, 2025
Share count, 1 year
+41.6%
2024-12-31 to 2025-12-31 · +39.0% over 3 years
Going-concern doubt
No
20-F filed April 7, 2026
Insider net buying, 12 months
$423K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-07
Cash and burn$210.6M cash; operating cash flow -$5.1M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey, United StatesPCAOB Form AP 2026-04-21
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $577K, sold $154K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$46.3M-$20.6M$210.6MNo debt tagsNeeds four quarters20-F 2026-04-07
FY 2024
2024-12-31
Not filed-$22.2M-$52.7M$68.3MNo debt tagsNeeds four quarters20-F 2026-04-07
FY 2023
2023-12-31
$632K-$207.7M-$183.8M$291.5M$4.2M$632K20-F 2026-04-07
FY 2022
2022-12-31
-$1.6M-$371.1M-$159.9M$342.9M$2.7M-$1.6M20-F 2025-04-03
FY 2021
2021-12-31
$13.8M-$365.9M-$152.7M$552.9MNo debt tags$13.8M20-F 2022-04-29
FY 2020
2020-12-31
$236.4M$72.2M$66.4M$729.3MNo debt tags$236.4M20-F 2021-04-28
FY 2019
2019-12-31
$4.3M-$208.6M-$124.7M$163.4M$7.2M$4.3M20-F 2020-04-29

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-6.6%
1 month-34.1%
3 months-55.3%
Year to date-78.6%
1 year-79.6%
From 52-week high-81.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RTSNRetension Pharmaceuticals Inc.$11.46-6.60%$90.3M
PMVPPMV Pharmaceuticals Inc.$1.19-6.30%$89.9M
NRXPNRX Pharmaceuticals Inc.$2.15-1.83%$93.8M
ANIXAnixa Biosciences Inc.$2.55-2.67%$88.6M
EQEquillium Inc.$1.15-10.85%$94.7M
HURATuHURA Biosciences Inc.$1.33-4.32%$87.5M
KZIAKazia Therapeutics Limited$5.60-15.41%$87.1M
GNLXGenelux Corporation$1.92+2.95%$86.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier